. 2022 May 25;8(6):e09538. doi: 10.1016/j.heliyon.2022.e09538

Table 2.

Laboratory data of 139 patients with HBV-related HCC at baseline.

	Group 1 (n = 54)	Group 2 (n = 85)	χ2	P value
Albumin
(<35 g/L)	22/54 (40.70%)	33/85 (38.80%)	0.051	0.822
(≥35 g/L)	32/54 (59.30%)	52/85 (61.20%)	0.051	0.822
TBIL
(<20.5umol/L)	20/54 (37.00%)	23/85 (27.00%)	1.539	0.215
(≥20.5umol/L)	34/54 (63.00%)	62/85 (73.00%)	1.539	0.215
PTA
(<75%)	29/54 (53.70%)	33/85 (38.80%)	2.959	0.085
(≥75%)	25/54 (46.30%)	52/85 (61.20%)	2.959	0.085
AFP
(<400 ng/ml)	27/54 (50.00%)	36/85 (42.40%)	0.779	0.337
(≥400 ng/ml)	27/54 (50.00%)	49/85 (57.60%)	0.779	0.337
GGT
(<33 U/L)	51/54 (94.40%)	72/85 (84.70%)	3.075	0.080
(≥33 U/L)	3/54 (5.60%)	13/85 (15.30%)	3.075	0.080
PLT
(<100∗10⁹/L)	15/54 (27.80%)	21/85 (24.70%)	0.162	0.687
(≥100∗10⁹/L)	39/54 (72.20%)	64/85 (75.30%)	0.162	0.687

Group1, lenvatinib plus sintilimab treatment group; Group2, lenvatinib monotherapy group.

Total bilirubin (TBIL); Prothrombin time activity (PTA); Alpha fetoprotein (AFP); Gamma-glutamyl transpeptidase (GGT); Platelets (PLT).